South & Central America Human Microbiome Market
No. of Pages: 128 | Report Code: BMIRE00032120 | Category: Life Sciences
No. of Pages: 128 | Report Code: BMIRE00032120 | Category: Life Sciences
The South & Central America human microbiome market size is expected to reach US$ 147.22 million by 2031 from US$ 39.65 million in 2023. The market is estimated to record a CAGR of 17.8% from 2023 to 2031.
The human microbiome market in South & Central America is further segmented into Brazil, Argentina, and the Rest of South & Central America. The presence of well-developed and established healthcare sectors, an increase in support from governments, and a rise in research and development are creating favorable conditions for the growth of the market in this region. Further, the growing prevalence of chronic diseases and the increasing adoption of unhealthy lifestyles are likely to boost the demand for human microbiome products and services.
South & Central America Human Microbiome Market Segmentation Analysis:
Key segments that contributed to the derivation of the South & Central America human microbiome market analysis are type, application, and disease type.
The potential of the human microbiome to transform healthcare industry has led to a recent surge in investments in research and development. Trillions of bacteria, fungi, and viruses that live in and on the human body make up the human microbiome, which is essential to good health as well as the prevention and treatment of diseases. The development of therapies based on microbiomes is receiving significant funding from biotech startups and pharmaceutical companies. One of the first microbiome startups in India, Xome Life Sciences, for example, focuses on every facet of the microbiome. The company is in the field and is developing prognostic, diagnostic, and therapeutic tools based on microbiomes to help people live healthier lives and make better decisions about their health. A recent FDA-approved treatment developed by Seres Therapeutics for recurrent Clostridium difficile infection is one of the many gastrointestinal diseases targeted by microbiome-based drugs. Vedanta Biosciences raised substantial money to build their pipeline of immunotherapies derived from microbiomes for autoimmune disorders and cancer. Notable investors such as Seventure Partners and Flagship Pioneering are actively funding companies that analyze microbiome data, reflecting a growing recognition of the microbiome's role in health. Thus, significant investment in research and development likely drives advancements in precision medicine and therapeutic interventions, thereby creating ample opportunities in the market.
Based on country, the South & Central America human microbiome market comprises Brazil, Argentina, and the Rest of South & Central America. Brazil held the largest share in 2023.
According to an article published in the Brazilian Journal of Infectious Diseases in 2023, a comprehensive study funded by research institutes in Brazil was conducted to analyze the sputum microbiome of patients with cystic fibrosis in Brazil. This study found a high Burkholderia cepacia complex (Bcc) in the sputum of cystic fibrosis patients using microbiome analysis. If this method can predict Bcc presence, it could help anticipate antibiotic treatment to prevent bacterial growth in the airways. Thus, ongoing studies are anticipated to bring possible diagnostics and treatments for various chronic diseases in Brazil, increasing the demand for human microbiomes.
Pharmaceutical companies and biotech startups are investing in development of innovative microbiome therapeutics, leading to the introduction of new products in the market. For instance, in April 2023, researchers at Nintx, a startup in São Paulo, Brazil, partnered with federal institutions and private-sector corporations to develop new drugs from plant-based natural products. The startup received a US$ 3 million investment from the venture capital firm Pitanga in 2022 to expedite bringing these drugs to market. Thus, the growing research studies and investments by pharmaceutical companies are fueling the growth of the human microbiome market in Brazil.
South & Central America Human Microbiome Market Company Profiles
Some of the key players operating in the market include MaaT Pharma; Ferring Holdings SA; AOBiome Therapeutics Inc; Finch Therapeutics Group Inc; Seres Therapeutics Inc; Merck & Co Inc; Rebiotix, Inc.; Yakult Honsha Co., Ltd.; IFF Nutrition & Biosciences; and Synthetic Biologics, Inc. among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
South & Central America Human Microbiome Market Research Methodology :
The following methodology has been followed for the collection and analysis of data presented in this report:
The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:
Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
The South & Central America Human Microbiome Market is valued at US$ 39.65 Million in 2023, it is projected to reach US$ 147.22 Million by 2031.
As per our report South & Central America Human Microbiome Market, the market size is valued at US$ 39.65 Million in 2023, projecting it to reach US$ 147.22 Million by 2031. This translates to a CAGR of approximately 17.8% during the forecast period.
The South & Central America Human Microbiome Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the South & Central America Human Microbiome Market report:
The South & Central America Human Microbiome Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The South & Central America Human Microbiome Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the South & Central America Human Microbiome Market value chain can benefit from the information contained in a comprehensive market report.
Office No. 1011, First floor, Farena Corporate Park, Magarpatta-Mundhwa road, Pune - 411028, Maharashtra, India
UK+442030260021, US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For South & Central America Human Microbiome Market
